Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 11-13-2023 | 09-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connec...
FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extend...
Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diver...
Baird analyst Joel Beatty downgrades Ambrx Biopharma (NASDAQ:AMAM) from Outperform to Neutral and announces $28 price target.
JMP Securities analyst Reni Benjamin downgrades Ambrx Biopharma (NASDAQ:AMAM) from Market Outperform to Market Perform.
B. Riley Securities analyst Yuan Zhi downgrades Ambrx Biopharma (NASDAQ:AMAM) from Buy to Neutral and raises the price targe...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow ...
